Every material Form 8-K Processa Pharmaceuticals, Inc. has filed with the SEC since October 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Processa sent a stockholder letter on November 5, 2026, reviewing its July acquisition of Vidya Therapeutics and the concurrent private placement of approximately $200 million. The letter says the approximately 2.8 million common shares outstanding represent only a small part of an expected 309.3 million-share as-converted count after Series A preferred conversion, which is subject to stockholder approval. Stockholders must vote separately at two special meetings, and the company says the July financing is expected to fund operations into the second half of 2029.
The Vidya acquisition and private placement closed in July; the financing generated approximately $183.3 million in net proceeds.
Expected capitalization: 2.8 million common shares outstanding plus 306.5 million Series A preferred as-converted, for 309.3 million total, subject to stockholder approval.
Definitive proxy materials for the first special meeting were filed October 22, 2026, and mailing has commenced; the second meeting's proxy is forthcoming.
The FDA cleared the IND for a planned Phase 2 clinical trial of VT-7208 in chronic spontaneous urticaria.
Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026, under an employment letter with a $700,000 annual base salary. The filing also discloses compensation for non-employee executive chair Dr. Sheila Gujrathi, and both executives' planned option grants depend on stockholder approval of the 2027 Equity Incentive Plan.
Flesher: $700,000 annual base salary and a discretionary target bonus of up to 60% of base salary beginning in fiscal 2027.
Planned option grant to Flesher equal to 3.0% of fully-diluted outstanding capital stock, contingent on stockholder approval of the 2027 Equity Incentive Plan at the Conversion Special Meeting.
Dr. Sheila Gujrathi, non-employee executive chair: $300,000 annual base compensation and a planned option grant equal to 1.5% of fully-diluted outstanding capital stock.
A November 4, 2026 press release announced Flesher's appointment and other leadership appointments.
Justin Yorke resigned as chair of Processa's board on October 27, 2026, and the board appointed Dr. Sheila Gujrathi as non-employee Executive Chair on October 28, effective immediately; Yorke remains a board member. The October 29 press release also reported FDA clearance of an IND for a Phase 2 study of VT-7208 in chronic spontaneous urticaria and said cash is expected to fund operations into the second half of 2029.
Justin Yorke resigned as board chair on October 27, 2026 and remains a board member.
Dr. Sheila Gujrathi was appointed non-employee Executive Chair on October 28, 2026, effective immediately.
The FDA cleared the IND for a Phase 2 CSU study of VT-7208 planned to enroll approximately 120 adults.
The company expects its cash resources to support operations into the second half of 2029.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Processa Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →